This retrospective analysis of refraction in low socioeconomic children from rural New South Wales and Australian Central Territory, Australia, reveals lower prevalence of myopia compared to reports from urban areas.
What do you do when your patient doesn’t respond to your low-dose atropine treatment? This case explores the nuances in navigating management when atropine doesn’t work as well as you might expect.
Non-responders are those children who have shown minimal efficacy of their treatment in myopia control studies, and it turns out that there’s around 15-20% of children who are classified this way across the major myopia control intervention studies. We look at non-responders in atropine, multifocal and myopia controlling contact lens, orthokeratology and DIMS spectacle lens studies, and what factors non-responders share across these studies.
When myopia progression seems to be faster than expected for a myopia control treatment, various factors can be at play, such as non-compliance, user error, high myopia, binocular vision, visual environment. Or you may have a non-responder on your hands. What should you do? Read more here.
Usually myopia and axial length are correlated. What does it mean when your patient has low myopia and high axial length? This case discusses various correlations between ocular and individual parameters and axial length.
How frequently should we measure axial length in myopia management practice, and how should it best direct our treatment strategy? Here we discuss how axial length change is related to refraction and ethnicity, and how to determine whether an axial length change is normal due to emmetropization or indicating myopia progression.
This review covers how well axial length relates to refraction and predicting future myopia, how to measure axial length, its value in orthokeratology and atropine management, how axial length influences a treatment plan and can you practice myopia management without it.
Myopia has multi-factorial causes with both nature and nurture contributing. In this research the authors used a retrospective cohort study to examine any differences in progression rate with different ethnicities and greater understand who may be at increased risk of myopic progression.
You may be ready to cease treatment, or the patient has done so of their own accord. Then you observe that the rate of myopic progression accelerates again – a myopia rebound effect. When does this happen? Can you avoid it? What should you consider doing in practice?
In myopia development the sclera is at risk of deformation due to increasing axial length progression. This research investigates whether cross-linking treatment could be used to stiffen the sclera as a way to restrict axial eye elongation.
